The 13th Annual Conference is coming back to Washington, DC on June 19-20, 2023

2022 Conference Agenda

Day Two - June 7, 2022

7:30 AM

Continental Breakfast

8:25 AM

Biomarkers in the Emergency Department: Clinical Decision Rules and Risk Stratification

Chris Davlantes, MD, FACEP, Senior Director, Global Medical Affairs, Abbott Point of Care, Emergency Physician, Lenox Hill Hospital

8:55 AM

Advances in Experimental TBI Modeling Using CHIMERA

Cheryl Wellington, Ph.D., Professor, Dept of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia

9:25 AM

Advances in the Development of Neurosteroids for Acquired Brain Injury

In this presentation Dr. Parry will discuss recent advances in the development of novel neurosteroids for the treatment of traumatic brain injury. He will also discuss preclinical data and the clinical program for the novel neuroactive small molecule that Neurotrauma Sciences is developing for acute and extended brain injury treatment.
Tom Parry, Ph.D., Senior VP of Research & Development, Neurotrauma Sciences

9:55 AM

Morning Break

During our morning break you will have an opportunity to visit with our numerous exhibitors, peruse the scientific poster session, have a snack and a coffee and network/meet with colleagues

10:25 AM

Development of NA-184, A Selective Calpain-2 Inhibitor for the Treatment of TBI

Work in Dr. Baudry’s laboratory over the last 10 years has shown that prolonged brain calpain-2 activation following a variety of insults plays a critical role in brain pathology resulting from these insults, including neuronal damage, brain inflammation and cognitive impairment. His laboratory is collaborating with NeurAegis, Inc, to develop selective calpain-2 inhibitors for the treatment of a number of neurological disorders, including traumatic brain injury and concussions. They have identified a lead clinical candidate, NA-184, which significantly inhibits neuronal damage in rodent models of TBI, as well as a blood biomarker, P13BP, which reflects brain calpain-2 activation. He will discuss their plans to bring NA-184 to the clinic in early 2023.
Michel Baudry, Ph.D., Professor, Graduate School of Biomedical Sciences Western University of Health Sciences

10:55 AM

Quality of Life in Epilepsy: The Impact of Traumatic Brain Injury and Multimorbidities

Epilepsy is defined by the occurrence of multiple unprovoked seizures, but quality of life (QOL) in people with epilepsy is determined by multiple factors, in which psychiatric comorbidities play a pivotal role. It is well known that QOL is lower in people with epilepsy, but little is known about QOL in those with a history of traumatic brain injury (TBI)—the most common cause of new onset epilepsy in younger adults. Therefore, understanding the interplay between comorbidities and QOL across epilepsy phenotypes is an important step towards improved outcomes. This presentation reports the impact of QOL across distinct epilepsy phenotypes in a cohort of post-9/11 veterans with high rates of traumatic brain injury (TBI) who responded to a national survey from the Military INjuries—Understanding post-Traumatic Epilepsy [MINUTE] study. We describe results of the MINUTE study which examined the association of epilepsy and quality of life in a cohort from which we developed epilepsy phenotypes based on lifetime history of TBI, current seizure and seizure medication use.
Mary Jo Pugh, Ph.D., RN, Professor, Department of Medicine, Division of Epidemiology, University of Utah School of Medicine

11:25 AM

NOSTRA III Results on Ronopterin, a Specific iNOS Inhibitor for the Treatment of Moderate and Severe TBI

John Stover, MD, Ph.D., Chief Medical Officer, vasopharm

11:55 PM


We have a number of options for lunch locations this year. You can dine with colleagues and acquaintances in two separate locations or if you'd like to physically distance due to Covid concerns, you can bring your lunch into the meeting room, dine in your guest room or in a quiet corner of the common areas through the hotel.

12:55 PM

ENIGMA-TBI Consortium: Emerging Practices for Data Sharing, Curation and Harmonization

In an era of open science, the power of sharing ideas and data has transformed TBI research. ENIGMA is at the forefront of data sharing efforts in TBI research, with the goal to bring together experts around the world to share ideas and methods and test the limits of data combination. In this talk we focus on the latest developments in combining thousands of cases in an effort to determine where data can and perhaps cannot be combined meaningfully. Examples include leveraging machine learning and item response theory for data curation and harmonization for both behavioral and structural and functional brain imaging data types. We also discuss avenues for federated or "virtual" data sharing and analysis which can eliminate the on-site burden for data transfer in order to enhance collaboration. Finally, we discuss ongoing challenges to open science and possible approaches to expedite conservative data curation and harmonization.
Frank Hillary, Ph.D., Professor of Psychology and Neurology, Penn State University
Emily L. Dennis, Ph.D., Assistant Professor of Neurology, University of Utah School of Medicine

1:30 PM

Levocetirizine and Montelukast in the Treatment of Traumatic Brain Injury

In this presentation, Dr. May will provide a scientific overview of the clinical program for levocetirizine and montelukast for the treatment of TBI. He will provide clinical data to date as relates to the treatment of severe TBI and outcomes at 8 months. He will then discuss the details of his group's development plan for this oral, first-response injectable.
B. Chandler May, MD, Chief Executive Officer, Inflammatory Response Research, Clinical Scientist & Practicing Physician, Cottage Health
Todd Kilbaugh, MD, Associate Chair for Research, Anesthesia, and Critical Care Medicine, Children's Hospital of Philadelphia

2:00 PM

TBI-Related Neurodegeneration (TReND)

Far beyond tau pathologies identified in chronic traumatic encephalopathy (CTE), ‘TReND” is a new umbrella term that encompasses many neuropathological changes observed after both repetitive head impacts and single moderate to severe TBI. This presentation will address unique characteristics of these neuropathologies explore potential sources, including diffuse axonal injury.
Douglas H. Smith, MD, Robert A. Groff Professor of Teaching and Research in Neurosurgery, University of Pennsylvania Perelman School of Medicine

2:30 PM

Outcomes of an Intensive Trauma Treatment Program for Special Operations Forces Service Members and Veterans

This presentation will focus on outcomes of a two-week, intensive trauma treatment program for Special Operations Forces members and veterans presenting with neurotrauma and cooccurring psychiatric concerns. Self-report of psychiatric and functional outcomes will be presented. The presentation will provide an overview of the main components within the intensive trauma treatment program at the Home Base Program at Massachusetts General Hospital.
Lauren Brenner, Ph.D., Clinical Psychologist, Instructor, Harvard Medical School/Home Base, a Red Sox Foundation and Massachusetts General Hospital Program

3:00 PM

End of Conference

Contact Us

Arrowhead Publishers & Conferences
PO Box 96
Chanhassen, MN 55317


About Us

Arrowhead Publishers' conferences offer more than simply presentations; we offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward.


Join Our TBI R&D Network on LinkedIn